Ignyta Announces Second Quarter 2016 Company Highlights And Financial Results
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the second quarter ended June 30, 2016. Ignyta will not be conducting a conference call in conjunction with this release.
“During the second quarter, we continued to make significant advancements toward our objective of becoming a leading precision medicine oncology company and offering cancer patients potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
“During the second quarter, we continued to make significant advancements toward our objective of becoming a leading precision medicine oncology company and offering cancer patients potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.